Business Wire

Passwords on the Rise Despite Evidence That They Are Increasingly Unable to Protect, Finds Thales

6.5.2020 09:00:00 EEST | Business Wire | Press release

Share

According to the 2020 Thales Access Management Index – Europe and Middle East Edition 1 nearly a third (29%) of organisations in Europe and the Middle East still see usernames and passwords as one of the most effective means to protect access to their IT infrastructure, two years after the inventor of the complex static password admitted they don’t work. In fact, 67% of respondents indicate that their organisations plan to expand its use of usernames and passwords in the future. This continued reliance on outdated security comes despite IT leaders revealing it is increasingly easier (48%) to sell the need for security to their boards compared to last year (29%).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200505005035/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Thales)

Surveying 400 IT decision-makers across Europe and the Middle East, Thales’s new research found that the majority (57%) of IT professionals revealed that unprotected infrastructure is one of the biggest targets for cyber-attacks. Therefore any organization utilising it, as a result of business pressure driving them to adopt digital transformation technologies, are likely to be putting themselves at a higher level of risk.

Solving the Security vs. Convenience Conundrum

With the Covid-19 global pandemic causing many companies to work from home, IT departments are battling to provide employees with both security and convenience. In fact, over two-thirds (67%) of European IT leaders say their security teams feel under pressure to provide convenient access to applications and cloud services for users, but still maintain security – an indication they’re struggling to balance their digital transformation and security priorities. To this end, 96% believe that strong authentication and access management solutions can facilitate secure cloud adoption. Over three-quarters (76%) also revealed employee authentication needs to be able to support secure access to a broad range of services including virtual private networks and cloud applications.

Making small improvements

While some organisations still rely on legacy authentication methods like usernames and passwords, growing awareness of the threats is prompting action with almost all (94%) organizations having changed their security policies around access management in the last 12 months. Staff training on security and access management (47%), increasing spend on access management (43%), and access management becoming a board priority (37%), have all seen an increased focus. This is set to pay off in compliance terms too, with nearly all (98%) European respondents admitting controlling who has access to their company’s data. This will help them meet data regulation requirements like GDPR.

“As more and more businesses move to adopt cloud-based services for CRM, email, employee collaboration and IT infrastructure as part of their digital transformation strategies, the struggle to extend old solutions, designed to protect internal resources, to the outside world becomes very problematic. Often, in an effort to adapt to the new working habits of users connecting from anywhere, which is increasingly pertinent right now and will become standard moving forward, businesses tend to revert back to old password-based logins for cloud services in despair. This is knowingly increasing their security exposure to credential stuffing and phishing attacks,” said Francois Lasnier, Vice President for Access Management solutions at Thales.

Two steps forward, one step back

Looking ahead, some IT leaders are set to potentially use their influence at board level more wisely, with investment in the use of more secure methods such as biometric authentication (75%) and smart SSO (81%) set to increase in the next year. However, a third (67%) still plan to expand their use of usernames and passwords, which is a similar size to those intending to further utilise passwordless authentication methods (70%).

“For a long time, the biggest battle IT leaders have faced is increasing board awareness around taking the threat of security seriously,” Lasnier continued. “Now that they have that buy in, the focus should be on highlighting the importance access management plays in implementing a zero trust security policy to their executive management. With this in place, risk management professionals will be able to put in place a ‘Protect Everywhere - Trust Nobody’ approach as they expand in the cloud.”

1 The 2020 Access Management Index, is a survey of 400 executives in 7 countries in Europe and the Middle East with responsibility for, or influence over, IT and data security. The survey, reporting and analysis was conducted by Vanson Bourne , commissioned by Thales.

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €18.4 billion in 2019.

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT

Thales Group
Security
Download HD photos

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations
Security
Constance Arnoux
+33 (0)1 57 77 91 58
constance.arnoux@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye